Kura Oncology, Inc.

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Kura Oncology is in Stage 2, the uptrend phase, now in week 18 (since Jun 22, 2026). It closed at $9.86, 27.4% below its 52-week high and above its 200-day average, which is falling.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More about the company

$9.86

-0.20% today

$877M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is KURA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 16w

S4 43w

S2 16w

S2 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 4w → S2 16w → S3 8w → S2 6w → S3 8w → S4 43w → S1 7w → S2 16w → S3 9w → S4 4w → S1 8w → S2 18w current

Total tracked: 164 weeks across 13 stage runs.

KURA among Biotechnology180th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…180	KURAKura Oncology, Inc.	Stage 2 · wk 18	57	−10.7%

vs 52W High

-27.4%

$7.40 lo$13.59 hi

27.4% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 18

1w13w26w

Week 18, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

0.8%

200 DMA: $9.79 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.52x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.7%

-5.1%

+6.4%

YTD

-4.6%

+2.9%

Scan Membership

Breakout Watch

Latest: 2024-06-27

6 appearances in last 60 days. First seen: 2019-05-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 18 · Vol 0.52x

2026-10-21S2

Wk 18 · Vol 0.43x

2026-10-20S2

Wk 17 · Vol 0.76x

2026-10-19S2

Wk 17 · Vol 1.07x

2026-10-16S2

Wk 17 · Vol 0.89x

2026-10-15S2

Wk 17 · Vol 0.84x

2026-10-14S2

Wk 17 · Vol 0.93x

2026-10-13S2

Wk 16 · Vol 1.40x

2026-10-12S2

Wk 16 · Vol 0.63x

2026-10-09S2

Wk 16 · Vol 0.76x

2026-10-08S2

Wk 16 · Vol 0.85x

2026-10-07S2

Wk 16 · Vol 0.56x

Moving averages & range

50 DMA

$11.32

200 DMA

$9.79

52W High

$13.59

52W Low

$7.40

5D Low

$9.08

Resistance levels (recent highs)

20d High

$10.81

60d High

$13.59

120d High

$13.59

250d High

$13.59

Next resistance

+9.6%

to 20d High

ROE

-167.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 18.1

Kura Oncology: quick answers

What stage is Kura Oncology in?

As of Oct 22, 2026, Kura Oncology (KURA) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 22, 2026 and is in week 18. What the four stages mean

Is Kura Oncology in an uptrend?

Yes. Kura Oncology is in a Stage 2 uptrend. It trades 0.8% above its 200-day average, which is falling.

How far is Kura Oncology from its 52-week high?

Kura Oncology closed at $9.86 on Oct 22, 2026, 27.4% below its 52-week high of $13.59. Its 52-week low is $7.40.

How has Kura Oncology performed over the past year?

As of Oct 22, 2026, Kura Oncology is up 2.9% over the past year and down 4.6% so far in 2026.

Which sector and industry is Kura Oncology in?

Kura Oncology is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.